Adjuvant capecitabine for early triple-negative breast cancer: A meta-analysis of randomized controlled trials

被引：1
|
作者：
Liu, Mei [1 ]
Fang, Huiying [1 ]
Qian, Shengqiang [2 ]
机构：
[1] Chongqing Univ, Chongqing Key Lab Translat Res Canc Metastasis &, Canc Hosp, Chongqing 400030, Peoples R China
[2] Chongqing Hosp Tradit Chinese Med, Dept Urol, Chongqing 400000, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2022年 / 45卷 / 09期
关键词：
D O I：
10.1016/j.asjsur.2022.01.039
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：1748 / 1750
页数：3
相关论文
共 50 条
  • [21] Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
    Feng Ye
    Lei Bian
    Jiahuai Wen
    Ping Yu
    Na Li
    Xiaoming Xie
    Xi Wang
    [J]. BMC Cancer, 22
  • [22] Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
    Ye, Feng
    Bian, Lei
    Wen, Jiahuai
    Yu, Ping
    Li, Na
    Xie, Xiaoming
    Wang, Xi
    [J]. BMC CANCER, 2022, 22 (01)
  • [23] Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
    Mastrantoni, Luca
    Garufi, Giovanna
    Di Monte, Elena
    Maliziola, Noemi
    Pasqualoni, Mariangela
    Pontolillo, Letizia
    Pannunzio, Sergio
    Cannizzaro, Maria Chiara
    Di Bello, Armando
    Fabi, Alessandra
    Palazzo, Antonella
    Tortora, Giampaolo
    Bria, Emilio
    Orlandi, Armando
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [24] Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials
    Xu, Ling
    Zhang, Zhuo
    Xiang, Qian
    Liu, Qianxin
    Duan, Xuening
    Liu, Yinhua
    Cui, Yimin
    [J]. CLINICAL BREAST CANCER, 2019, 19 (05) : E578 - E588
  • [25] Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
    Saroj Niraula
    Bishal Gyawali
    [J]. Breast Cancer Research and Treatment, 2019, 173 : 103 - 109
  • [26] Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer
    Steger, G. G.
    Barrios, C.
    O'Shaughnessy, J.
    Martin, M.
    Gnant, M.
    [J]. CANCER RESEARCH, 2010, 70
  • [27] Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
    Niraula, Saroj
    Gyawali, Bishal
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (01) : 103 - 109
  • [28] Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis
    Latif, Farah
    Jabbar, Hira Bint Abdul
    Malik, Hamna
    Sadaf, Humaira
    Sarfraz, Azza
    Sarfraz, Zouina
    Cherrez-Ojeda, Ivan
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (02) : 229 - 235
  • [29] Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
    Li, Yunhai
    Xing, Lei
    Li, Fan
    Liu, Hong
    Gan, Lu
    Yang, Dejuan
    Wang, Mengxue
    Yin, Xuedong
    Li, Hongyuan
    Ren, Guosheng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
    Huo, Xingfa
    Shen, Guoshuang
    Liu, Zhen
    Liang, Yuhua
    Li, Jinming
    Zhao, Fuxing
    Ren, Dengfeng
    Zhao, Jiuda
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 168
12345